Cytogenetic Studies in Acute Leukemia and Multiple Myeloma: Companion to CALGB Treatment Studies For Previously Untreated Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS) or Multiple Myeloma (MM) Patients
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 9,000
- 试验地点
- 137
- 主要终点
- Correlate specific karyotype groups with selected molecular abnormalities as studied in CALGB leukemia protocols
研究概览
简要总结
Chromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It may also improve the ability to predict the course of disease and the selection of therapy. Institutions must have either an Alliance-approved cytogeneticist or an agreement from an Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical Trials in Oncology website.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Correlate specific karyotype groups with selected molecular abnormalities as studied in CALGB leukemia protocols
时间窗: Up to 10 years
To correlate specific karyotype groups with multidrug resistance data
时间窗: Up to 10 years
Determine the incidence of specific less common primary as well as common secondary chromosome abnormalities in adult AML, ALL, MDS and MM
时间窗: Up to 10 years
Correlate specific (normal or various primary and secondary chromosomal abnormalities) with clinical and laboratory parameters
时间窗: Up to 10 years
Correlate specific karyotype groups with response rates, response duration, survival and cure in patients treated with various induction and post-induction regimens
时间窗: Up to 10 years
To correlate specific karyotype groups with epidemiologic data (toxic exposure and family history)
时间窗: Up to 10 years
To determine karyotype changes at relapse and the influence of the type of change (or no change) in karyotype at relapse on subsequent clinical course
时间窗: up to 10 yeras
To identify new chromosome abnormalities important in leukemogenesis
时间窗: Up to 10 years
次要结局
未报告次要终点